About: Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic
Creator	Khan, Khan, Mubarak Parab, Sapna Paranjape, Mandar Parab, Sapna, Ramkrishna Mubarak, M Parab, R Sapna, Dr
Source	Elsevier; Medline; PMC
abstract	SARS CoV 2 is very much homologous in structure to SARS CoV. Review of literature suggests the in-vitro virucidal action of povidone iodine in SARS CoV and MERS. The oropharynx and nasopharynx are target sites of SARS CoV 2. A significant proportion of COVID 19 sufferers are asymptomatic, but shedding these viral particles, PVP-I has been shown to be a safe therapy when used as a mouthwash or taken nasally or used during ophthalmic surgeries. AIMS: 1. To propose the use of 0.5% Povidone iodine gargles and nasal drops as prerequisite for office based nose and throat examination and procedures during COVID 19 pandemic. 2. To assess tolerability of 0.5% PVP-I in patients and in healthcare workers. MATERIALS AND METHODS: 0.5% PVP-I solution is prepared from commercially available 10% PVP-I solution. Patients were instructed to put 0.5% PVP-I drops in nose and rinse mouth with gargle prior examinations for 30 s. For endoscopic procedure (nasal and throat) nasal douching and gargling to be started one day prior. Douching and rinsing to be repeated just before procedures. Nasal packing with 0.5% PVP-I along with 4% xylocaine/adrenaline solution, tolerability and any allergic reaction noted. RESULTS: The patient and health care workers tolerated the 0.5%. No allergy was noted. CONCLUSION: We propose the use of 0.5% PVP-I in healthcare workers and their patients to minimise the risk of spread of the disease in addition to the recommended PPE.
has issue date	2020-06-18(xsd:dateTime)
bibo:doi	10.1016/j.amjoto.2020.102618
bibo:pmid	32574894
has license	no-cc
sha1sum (hex)	a22bc8b305be9ebfb75d2e71a23706796143dfa4
schema:url	https://doi.org/10.1016/j.amjoto.2020.102618
resource representing a document's title	Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic
has PubMed Central identifier	PMC7301800
has PubMed identifier	32574894
schema:publication	Am J Otolaryngol
resource representing a document's body	covid:a22bc8b305be9ebfb75d2e71a23706796143dfa4#body_text
is schema:about of	named entity 'literature' named entity 'patient' named entity 'particles' named entity 'drops' named entity 'pandemic' named entity 'prior' named entity 'prepared' named entity 'repeated' named entity 'drops' named entity 'otorhinolaryngology' named entity 'PRE' named entity 'PANDEMIC' named entity 'packing' named entity 'PPE' named entity 'ophthalmic' named entity 'healthcare' named entity 'virucidal' named entity 'allergic reaction' named entity 'Patients' named entity 'tolerability' named entity 'healthcare' named entity 'solution' named entity 'rinsing' named entity 'patients' named entity 'Povidone iodine' named entity 'SARS CoV' named entity 'SARS CoV' named entity 'SARS CoV' named entity 'health care workers' named entity 'oropharynx' named entity 'viral particles' named entity 'PVP-I' named entity 'COVID 19' named entity 'gargling' named entity 'COVID 19 pandemic' named entity 'mouthwash' named entity 'saliva' named entity 'Ear, Nose and Throat' named entity 'oropharynx' named entity 'ophthalmic' named entity 'iodine' named entity 'saliva' named entity 'PVP-I' named entity 'COVID 19' named entity 'endoscopy' named entity 'PVP-I' named entity 'oral cavity' named entity 'saliva' named entity 'handwashing' named entity 'ophthalmic surgery' named entity 'coronaviruses' named entity 'COVID' named entity 'thyroid function' named entity 'false negative' named entity 'dermatitis' named entity 'coronavirus' named entity 'SARS-CoV-2' named entity 'antiseptics' named entity 'PVP-I' named entity 'nasal administration' named entity 'PVP-I' named entity 'PVP-I' named entity 'radioactive iodine treatment' named entity 'COVID-19' named entity 'mucosa' named entity 'oropharynx' named entity 'nostril' named entity 'Povidone Iodine' named entity 'virucidal' named entity 'mucins' named entity 'iodine' named entity 'gargles' named entity 'infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software